Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 13, 2009, Pages 3892-3901

  Jong, Yeon Hwang ^a   Arnold, Leggy A ^a   Zhu, Fangyi ^a   Kosinski, Aaron ^a   Mangano, Thomas J ^a,b   Setola, Vincent ^a,b   Roth, Bryan L ^a,b   Guy, R Kiplin ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOKETONE DERIVATIVE; BENZENE DERIVATIVE; CARBONYL DERIVATIVE; HORMONE RECEPTOR BLOCKING AGENT; ION CHANNEL; NUCLEAR RECEPTOR COACTIVATOR 2; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR COACTIVATOR BINDING INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FRIEDEL CRAFTS REACTION; HUMAN; HUMAN CELL; HYDROPHOBICITY; MANNICH REACTION; PHYSICAL CHEMISTRY; PKA; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

AMINES; ANTITHYROID AGENTS; CELL LINE; CELL SURVIVAL; HUMANS; INHIBITORY CONCENTRATION 50; ION CHANNELS; KETONES; PROTEIN BINDING; RECEPTORS, THYROID HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67649909039     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9002704     Document Type: Article

References (30)

1. Yen, P. M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 2001, 81, 1097-1142.
2. Malm, J. Thyroid hormone ligands and metabolic diseases. Curr. Pharm. Des. 2004, 10, 3525-3532.
3. Aranda, A.; Pascual, A. Nuclear hormone receptors and gene expression. Physiol. Rev. 2001, 81, 1269-1304.
4. Harvey, C. B.; Williams, G. R. Mechanism of thyroid hormone action. Thyroid 2002, 12, 441-446.
5. Williams, G. R. Cloning and characterization of two novel thyroid hormone receptor beta isoforms. Mol. Cell. Biol. 2000, 20, 8329-8342.
6. Brent, G. A. Tissue-specific actions of thyroid hormone: insights from animal models. Rev. Endocr. Metab. Disord. 2000, 1, 27-33.
7. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M. The nuclear receptor superfamily: the second decade. Cell 1995, 83, 835-839.
8. Ribeiro, R. C.; Apriletti, J. W.; Wagner, R. L.; West, B. L.; Feng, W.; Huber, R.; Kushner, P. J.; Nilsson, S.; Scanlan, T.; Fletterick, R. J.; Schaufele, F.; Baxter, J. D. Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies. Recent Prog. Horm. Res. 1998, 53, 351-392, discussion 392-354.
9. Nguyen, N. H.; Apriletti, J. W.; Cunha Lima, S. T.; Webb, P.; Baxter, J. D.; Scanlan, T. S. Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J. Med. Chem. 2002, 45, 3310-3320.
10. Lim, W.; Nguyen, N. H.; Yang, H. Y.; Scanlan, T. S.; Furlow, J. D. A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J. Biol. Chem. 2002, 277, 35664-35670.
11. Hashimoto, A.; Shi, Y.; Drake, K.; Koh, J. T. Design and synthesis of complementing ligands for mutant thyroid hormone receptor TRbeta (R320H): a tailor-made approach toward the treatment of resistance to thyroid hormone. Bioorg. Med. Chem. 2005, 13, 3627-3639.
12. Flamant, F.; Gauthier, K.; Samarut, J. Thyroid hormones signaling is getting more complex: STORMs are coming. Mol. Endocrinol. 2007, 21, 321-333.
13. Arnold, L. A.; Estebanez-Perpina, E.; Togashi, M.; Jouravel, N.; Shelat, A.; McReynolds, A. C.; Mar, E.; Nguyen, P.; Baxter, J. D.; Fletterick, R. J.; Webb, P.; Guy, R. K. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J. Biol. Chem. 2005, 280, 43048-43055.
14. Arnold, L. A.; Estebanez-Perpina, E.; Togashi, M.; Shelat, A.; Ocasio, C. A.; McReynolds, A. C.; Nguyen, P.; Baxter, J. D.; Fletterick, R. J.; Webb, P.; Guy, R. K. A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Sci. STKE 2006, 2006, pl3.
15. Arnold, L. A.; Kosinski, A.; Estebanez-Perpina, E. R. J. F.; Guy, R. K. Inhibitors of the Interaction of a Thyroid Hormone Receptor and Coactivators: Preliminary Structure-Activity Relationships. J. Med. Chem. 2007, 50, 5269-5280.
16. Estebanez-Perpina, E.; Arnold, L. A.; Jouravel, N.; Togashi, M.; Blethrow, J.; Mar, E.; Nguyen, P.; Phillips, K. J.; Baxter, J. D.; Webb, P.; Guy, R. K.; Fletterick, R. J. Structural Insight into the Mode of Action of a Direct Inhibitor of Coregulator Binding to the Thyroid Hormone Receptor. Mol. Endocrinol. 2007, 21, 2919-2928.
17. Bruhova, I.; Tikhonov, D. B.; Zhorov, B. S. Access and Binding of Local Anesthetics in the Closed Sodium Channel. Mol. Pharmacol. 2008, 74, 1033-1045.
18. Wright, S. N. Cardiotoxic and antiarrhythmic tertiary amine local anesthetics: sodium channel affinity vs sodium channel gating. Curr. Vasc. Pharmacol. 2003, 1, 239-242.
19. Mannich, C. Synthesis of b-ketonic bases. Arch. Pharm. 1917, 255, 261-276.
20. Lehmann, F.; Pilotti, A.; Luthman, K. Efficient large scale microwave assisted Mannich reactions using substituted acetophenones. Mol Diversity 2003, 7, 145-152.
21. Leadbeater, N. E.; Torenius, H. M.; Tye, H. Microwave-assisted Mannich-type three-component reactions. Mol Diversity 2003, 7, 135-144.
22. Sebille, S.; Gall, D.; de Tullio, P.; Florence, X.; Lebrun, P.; Pirotte, B. Design, synthesis, and pharmacological evaluation of R/S-3,4-dihydro- 2,2-dimethyl-6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: toward tissue-selective pancreatic beta-cell KATP channel openers structurally related to (±)-cromakalim. J. Med. Chem. 2006, 49, 4690-4697.
23. Galinis-Luciani, D.; Nguyen, L.; Yazdanian, M. Is PAMPA a useful tool for discovery? J. Pharm. Sci. 2007, 96, 2886-2892.
24. Obata, K.; Sugano, K.; Machida, M.; Aso, Y. Biopharmaceutics classification by high throughput solubility assay and PAMPA. Drug Dev. Ind. Pharm. 2004, 30, 181-185.
25. Alsenz, J.; Kansy, M. High throughput solubility measurement in drug discovery and development. Adv. Drug Delivery Rev. 2007, 59, 546-567.
26. Johansson, T.; Weidolf, L.; Jurva, U. Mimicry of phase I drug metabolism - novel methods for metabolite characterization and synthesis. Rapid Commun. Mass Spectrom. 2007, 21, 2323-2331.
27. Shetty, H. U.; Nelson, W. L. Chemical aspects of metoprolol metabolism. Asymmetric synthesis and absolute configuration of the 3-[4-(1-hydroxy-2- methoxyethyl)phenoxy]-1-(isopropylamino)-2-propanols the diastereomeric benzylic hydroxylation metabolites. J. Med. Chem. 1988, 31, 55-59.
28. Engst, W.; Landsiedel, R.; Hermersdorfer, H.; Doehmer, J.; Glatt, H. Benzylic hydroxylation of 1-methylpyrene and 1-ethylpyrene by human and rat cytochromes P450 individually expressed in V79 Chinese hamster cells. Carcinogenesis 1999, 20, 1777-1785.
29. Hansch, C. L. A.; Taft, R. W. A survey of hammett substituent constants and resonance and field parameters. Chem. Rev. 1991, 91, 165-195.
30. Hansch, C. L. A.; Hoekman, D. H. Exploring QSAR: Hydrophobic, Electronic, and Steric Constants; American Chemical Society: Washington, DC, 1995; pp 219-304.